Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model
Open Access
- 23 November 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (23) , 5878
Abstract
Large-scale clinical trials, such as the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies, have shown that the administration of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, suppresses the progression of diabetic retinopathy. In this paper, we reveal a therapeutic effect of a selective PPARα modulator (SPPARMα), pemafibrate, against pathological angiogenesis in murine models of retinopathy. Oxygen-induced retinopathy (OIR) was induced in C57BL/6J mice by exposure to 85% oxygen from postnatal day eight (P8) for 72 h. Vehicle, pemafibrate or fenofibrate was administrated by oral gavage from P12 to P16 daily. Administration of pemafibrate, but not fenofibrate, significantly reduced pathological angiogenesis in OIR. After oral pemafibrate administration, expression levels of downstream PPARα targets such as acyl-CoA oxidase 1 (Acox1), fatty acid binding protein 4 (Fabp4), and fibroblast growth factor 21 (Fgf21) were significantly increased in the liver but not in the retina. A significant increase in plasma FGF21 and reduced retinal hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor A (Vegfa) were also observed after this treatment. In an in vitro HIF-luciferase assay, a long-acting FGF21 analogue, but not pemafibrate, suppressed HIF activity. These data indicate that SPPARMα pemafibrate administration may prevent retinal pathological neovascularization by upregulating FGF21 in the liver.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (15K10881, 18K09424)
- Kowa Life Science Foundation (N/A)
This publication has 37 references indexed in Scilit:
- Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes ModelsDiabetes, 2012
- Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic NicheCell Stem Cell, 2011
- Effects of Medical Therapies on Retinopathy Progression in Type 2 DiabetesNew England Journal of Medicine, 2010
- von Hippel-Lindau protein regulates transition from the fetal to the adult circulatory system in retinaDevelopment, 2010
- Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesisNature Protocols, 2009
- Glycoxidized particles mimic lipofuscin accumulation in aging eyes: a new age-related macular degeneration model in rabbitsGraefe's Archive for Clinical and Experimental Ophthalmology, 2007
- Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptorsNature Clinical Practice Endocrinology & Metabolism, 2007
- The biology of VEGF and its receptorsNature Medicine, 2003
- Vascular endothelial growth factors and angiogenesis in eye diseaseProgress in Retinal and Eye Research, 2003
- Purification and Characterization of Hypoxia-inducible Factor 1Journal of Biological Chemistry, 1995